Log in to search using one of your social media accounts:

 

Exelon (Rivastigmine Tartrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 7, 2017 Category: Drugs & Pharmacology Source Type: news

Novartis slapped with $49m fine over kickbacks
South Korea regulators said today that it fined Swiss drugmaker Novartis (NYSE:NVS)$48.8 million for offering doctors kickbacks in exchange for recommending the company’s drugs to patients. The Ministry of Health and Welfare also decided to suspend insurance coverage of 9 variations of 2 drugs, including the Alzheimer’s drug Exelon, for 6 months, according to Reuters. Get the full story at our sister site, Drug Delivery Business News. The post Novartis slapped with $49m fine over kickbacks appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 27, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Pharmaceuticals Regulatory/Compliance Wall Street Beat Novartis Source Type: news

Smart meters use unsafe, cancer-causing technology
(NaturalNews) PECO is the biggest electric and natural gas provider in Philadelphia and a subsidiary of the Exelon Corporation, the largest provider of energy in the nation. Since 2012, PECO has been rolling out Smart Meters to just over 2 million Pennsylvania customers. PECO declares that using smart meters will give “faster, more convenient service,” which will allow the... (Source: NaturalNews.com)
Source: NaturalNews.com - November 28, 2016 Category: Consumer Health News Source Type: news

Exelon (rivastigmine, Exelon Patch)
Title: Exelon (rivastigmine, Exelon Patch)Category: MedicationsCreated: 10/19/2003 12:00:00 AMLast Editorial Review: 9/22/2016 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - September 22, 2016 Category: Geriatrics Source Type: news

Treatment of Alzheimer ’ s Disease
There is no cure for Alzheimer’s disease and no way to slow the progression of the disease. For some people in the early or middle stages of Alzheimer’s disease, medication such as tacrine (Cognex) may alleviate some cognitive symptoms. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) may keep some symptoms from becoming worse for a limited time. A fifth drug, memantine (Namenda), has also been approved for use in the United States. Combining memantine with other Alzheimer’s disease drugs may be more effective than any single therapy. One controlled clinical trial found that patients...
Source: Psych Central - August 17, 2016 Category: Psychiatry Authors: Jane Framingham, Ph.D. Tags: Alzheimer's Medications Memory and Perception Alzheimer's treatment Cognex donepezil Drug Exelon galanta Namenda Reminyl rivastigmine tacrine treatment of alzheimers Source Type: news

ExxonMobil Is Still Funding Climate Science Denier Groups
ExxonMobil officials may hem and haw when reporters ask them if the company still funds climate science denier organizations, but the numbers don't lie. The company says it acknowledges the reality of global warming and claims it supports a carbon tax, but its recently disclosed list of 2015 "public information and policy research" grantees shows it spent nearly $2 million last year on more than a dozen think tanks, advocacy groups and associations that dispute climate science and disparage renewable energy. That's significant from both a legal and political perspective. There are legal implications because E...
Source: Science - The Huffington Post - July 13, 2016 Category: Science Source Type: news

Intrigued by the Marriott deal? Here are 5 other M&A deals that captivated Greater Washington
If there's one thing we've learned this month it's that the M&A world isn't for the faint-hearted. The D.C. Public Service Commission finally ended its will-it-or-won't-it game, giving approval for Pepco Holdings Inc. and Exelon Corp. to close their $6.8 billion merger. Which they did. Within hours. And Marriott International Inc. was engaged in a high-stakes game of financial chicken with the Chinese insurer Anbang over the potential acquisition of Starwood Hotels & Resorts Worldwide Inc. In the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 1, 2016 Category: Pharmaceuticals Authors: Andy Medici Source Type: news

Aurobindo Pharma gets final USFDA nod for dementia drug
Drug firm Aurobindo Pharma has received final approval from USFDA to manufacture and market Rivastigmine Tartrate Capsules USP. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 29, 2016 Category: Pharmaceuticals Source Type: news

MIT Energy Initiative welcomes Exelon as member for clean energy research
(MIT Energy Initiative) MIT Energy Initiative announces that national energy provider Exelon joins MITEI as a member to focus research support through MITEI's Low-Carbon Energy Centers. The Centers bring together researchers from multiple disciplines at MIT to engage with companies, governmental agencies, and other stakeholders to develop deployable clean energy technology solutions through a uniquely inclusive model. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 25, 2016 Category: Global & Universal Source Type: news

Dr Reddy's recalls Rivastigmine Tartrate capsules of 1.5 mg strength from US
Dr Reddy's Laboratories (DRL) has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 20, 2015 Category: Pharmaceuticals Source Type: news

rivastigmine, Exelon
Title: rivastigmine, ExelonCategory: MedicationsCreated: 10/19/2003 12:00:00 AMLast Editorial Review: 5/18/2015 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - May 18, 2015 Category: Geriatrics Source Type: news

Dollars for Prescribers: Top Medicare Prescribers for Acthar Have Links to Its Maker
The top four prescribers of the drug were promotional speakers, researchers or consultants. (Source: NYT)
Source: NYT - August 4, 2014 Category: American Health Authors: By CHARLES ORNSTEIN Tags: Medicare Forest Laboratories Inc FRX NYSE Acthar (Drug) Johnson & Johnson JNJ NYSE Drugs (Pharmaceuticals) Novartis AG NVS NYSE Health Insurance and Managed Care Exelon Corporation EXC NYSE Questcor Pharmaceuticals Incorporated QSC AME Source Type: news

Dollars for Prescribers: Top Medicare Prescribers for Acthar Have Links to Its Maker
The top four prescribers of the drug were promotional speakers, researchers or consultants. (Source: NYT Health)
Source: NYT Health - August 4, 2014 Category: Consumer Health News Authors: By CHARLES ORNSTEIN Tags: Medicare Forest Laboratories Inc FRX NYSE Acthar (Drug) Johnson & Johnson JNJ NYSE Drugs (Pharmaceuticals) Novartis AG NVS NYSE Health Insurance and Managed Care Exelon Corporation EXC NYSE Questcor Pharmaceuticals Incorporated QSC AME Source Type: news

Israel Prize in Medicine awarded to Hebrew University developer of Alzheimer's drug
(The Hebrew University of Jerusalem) The Israel Prize for Medicine will be awarded to the Hebrew University of Jerusalem's Prof. Marta Weinstock-Rosin, a professor emeritus at the School of Pharmacy-Institute for Drug Research in the Faculty of Medicine. Weinstock-Rosin is best known for developing Exelon, a blockbuster drug for the treatment of confusion and dementia related to Alzheimer's and Parkinson's diseases. She is also co-developer of Ladostigil, now undergoing Phase II clinical trials for prevention of Alzheimer's disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 3, 2014 Category: Biology Source Type: news

Exelon (Rivastigmine Tartrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 18, 2013 Category: Drugs & Pharmacology Source Type: news

Size No Problem for AD Med Skin Patch (CME/CE)
BOSTON (MedPage Today) -- Using a larger patch of rivastigmine (Exelon) does not appear to increase dermatologic reactions to the medication, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 18, 2013 Category: Cardiology Source Type: news

FDA Approves Exelon Patch for Severe Alzheimer'sFDA Approves Exelon Patch for Severe Alzheimer's
The rivastigmine transdermal system, already approved for mild to moderate AD, is now approved across all stages of the disease. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Exelon (rivastigmine) patches - all strengths - Novartis Pharmaceuticals UK Ltd - revised SPC
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates> SPC Changes Section 4.2 Posology and method of administration has been updated to state that 9.5 mg/24 hours is the recommended daily effective dose which should be continued for as long as the patient continues to demonstrate therapeutic benefit. If well tolerated and only after a minimum of six months of treatment at 9.5 mg/24 hours, the treating physician may consider increasing the dose to 13.3 mg/24 hours in patients who have demonstrated a meaningful cognitive deterioration (e.g. decrease in the MMSE) and/or functional decline (based on ph...
Source: NeLM - Mental Health - February 28, 2013 Category: Psychiatry Source Type: news

Exelon (rivastigmine) capsules and oral solution and patches - all strengths - Novartis Pharmaceuticals UK Ltd - revised SPC
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates> SPC Changes Section 4.8 Undesirable effects has been updated to include disseminated cutaneous hypersensitivity reactions (frequency not known). Additionally, decreased appetite, urinary incontinence (common), psychomotor hyperactivity (uncommon), erythema, urticaria, vesicles, allergic dermatitis (not known) have been added as additional adverse reactions that have been observed in patients with Alzheimer's dementia using Exelon transdermal patches.   Depression has been removed as an adverse reaction experienced by patients with demen...
Source: NeLM - Mental Health - February 25, 2013 Category: Psychiatry Source Type: news